FDA jurisdiction
Does drug supply chain tracing law have anything to do with selling research chemicals?
Plain English first, then the primary source. Education, not legal advice.
Interpretation
In short: prescription drug supply-chain rules govern traceability. RUO material sits outside that system, which is itself a documentation problem.
Plain English
The Drug Supply Chain Security Act (DSCSA) establishes a system for tracing certain prescription drugs as they move through the supply chain, aimed at protecting consumers from counterfeit, stolen, or otherwise harmful products. FDA maintains guidance and policy on how it applies to trading partners such as manufacturers, wholesalers, and dispensers.
DSCSA is built around the definition of a 'product' under the FD&C Act, which generally means an approved prescription drug. A compound that has never been approved as a prescription drug and is not being distributed as one is generally outside this specific tracing framework, though it may still be subject to other FD&C Act requirements discussed elsewhere in this library.
This is a useful example of how a law can be well known in the pharmaceutical industry without directly governing an unapproved research chemical, while other, more general FD&C Act provisions still can.
Why it matters
- Suppliers should not assume that being outside DSCSA's tracing requirements means they are outside all FDA jurisdiction.
Where the answer becomes fact-specific
The Foundation does not manufacture legal conclusions. These points change the analysis and may require qualified regulatory counsel.
- Whether a specific product or transaction is covered depends on the product's regulatory status and the role of each party in the chain of distribution.